The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis
Open accessAbstract
Background & aims Primary sclerosing cholangitis (PSC) is an orphan hepatobiliary disorder associated with inflammatory bowel disease (IBD). We aimed to estimate the risk of disease progression based on distinct clinical phenotypes in a large international cohort of patients with PSC.Methods We performed a retrospective outcome analysis of patients diagnosed with PSC from 1980 through 2010 at 37 centers in Europe, North America, and Australia. For each patient, we collected data on sex, clinician-reported age at and date of PSC and IBD diagnoses, phenotypes of IBD and PSC, and date and indication of IBD-related surgeries. The primary and secondary endpoints were liver transplantation or death (LTD) and hepatopancreatobiliary malignancy, respectively. Cox proportional hazards models were applied to determine the effects of individual covariates on rates of clinical events, with time-to-event analysis ascertained through Kaplan-Meier estimates.Results Of the 7121 patients in the cohort, 2616 met the primary endpoint (median time to event of 14.5 years) and 721 developed hepatopancreatobiliary malignancy. The most common malignancy was cholangiocarcinoma (n = 594); patients of advanced age at diagnosis had an increased incidence compared with younger patients (incidence rate: 1.2 per 100 patient-years for patients younger than 20 years old, 6.0 per 100 patient-years for patients 21-30 years old, 9.0 per 100 patient-years for patients 31-40 years old, 14.0 per 100 patient-years for patients 41-50 years old, 15.2 per 100 patient-years for patients 51-60 years old, and 21.0 per 100 patient-years for patients older than 60 years). Of all patients with PSC studied, 65.5% were men, 89.8% had classical or large-duct disease, and 70.0% developed IBD at some point. Assessing the development of IBD as a time-dependent covariate, Crohn's disease and no IBD (both vs ulcerative colitis) were associated with a lower risk of LTD (unadjusted hazard ratio [HR], 0.62; P < .001 and HR, 0.90; P = .03, respectively) and malignancy (HR, 0.68; P = .008 and HR, 0.77; P = .004, respectively). Small-duct PSC was associated with a lower risk of LTD or malignancy compared with classic PSC (HR, 0.30 and HR, 0.15, respectively; both P < .001). Female sex was also associated with a lower risk of LTD or malignancy (HR, 0.88; P = .002 and HR, 0.68; P < .001, respectively). In multivariable analyses assessing the primary endpoint, small-duct PSC characterized a low-risk phenotype in both sexes (adjusted HR for men, 0.23; P < .001 and adjusted HR for women, 0.48; P = .003). Conversely, patients with ulcerative colitis had an increased risk of liver disease progression compared with patients with Crohn's disease (HR, 1.56; P < .001) or no IBD (HR, 1.15; P = .002).Conclusions In an analysis of data from individual patients with PSC worldwide, we found significant variation in clinical course associated with age at diagnosis, sex, and ductal and IBD subtypes. The survival estimates provided might be used to estimate risk levels for patients with PSC and select patients for clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The close relationship with IBD is likely relevant, as shown by variable disease behaviour depending on the clinical presentation of IBD.6,8”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [6]
In the citing paper
“An important feature of PSC is the inherent risk of neoplasia at the affected mucosal surfaces, most commonly in the form of cholangiocarcinoma (CCA) and colorectal cancer.[5][6][7]”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [6]
In the citing paper
“CCA is very rarely seen in patients with small duct PSC.6”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [6]
In the citing paper
“most people with PSC have benign strictures leading to end-stage disease and will not develop hepatobiliary malignancy.6”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [6]
In the citing paper
“Data supporting that IBD (and its inflammatory activity) is important for PSC progression is that UC, as opposed to no IBD 368 or Crohns disease, is associated with faster PSC progression.6”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [6]
In the citing paper
“In a large, multicentre international retrospective study including 781 children and young people diagnosed with PSC, 67% fulfilled the diagnostic criteria for AIH, in contrast to 6.6% in a similar study including 7,121 adults, suggesting higher prevalence in the paediatric population.6,427”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [6]
In the citing paper
“In the retrospective outcome analysis of patients diagnosed with PSC from 1980 through 2010 at 37 centres in Europe, North America, and Australia including 7,121 patients, the incidence of CCA in 940 patients < -20 years-old was 1.2/100 patient-years increasing with age to 21/100 patientyears for those over the age of 60. 6”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [6]
In the citing paper
“Patients with associated UC were at higher risk of developing CCA.”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Contributions to Probability and Statistics: Essays in Honor of Harold Hotelling.
David, F. N., Olkin, I., Ghurye, S. G., Hoeffding, W., Madow, W. G., & Mann, H. B. (1961) · Journal of the Royal Statistical Society Series A (General) · doi:10.2307/2984135 · Cited by 1,914
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Assche, G. V., Dignass, A. U., Panés, J., Beaugerie, L., Karagiannis, J. A., Allez, M., Ochsenkühn, T., Orchard, T., Rogler, G., Louis, E. J., et al. (2010) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2009.12.003 · Cited by 1,444
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R. W., Fevery, J., Kalloo, A. N., Nagorney, D. M., Boberg, K. M., Shneider, B. L., & Gores, G. J. (2009) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,230
Self-citationDignass, A. U., Eliakim, R., Magro, F., Maaser, C., Chowers, Y., Geboes, K., Mantzaris, G. J., Reinisch, W., Colombel, J., Vermeire, S., et al. (2012) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2012.09.003 · Cited by 903
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.
Broomé, U., Olsson, R., Lööf, L., Bodemar, G., Hultcrantz, R., Danielsson, A., Prytz, H., Sandberg–Gertzén, H., Wallerstedt, S. M., & Lindberg, G. (1996) · Gut · doi:10.1136/gut.38.4.610 · Cited by 816
Boonstra, K., Weersma, R. K., van Erpecum, K. J., Rauws, E. A., Spanier, B. W. M., Poen, A. C., van Nieuwkerk, K. M., Drenth, J. P., Witteman, B. J., Tuynman, H. A., et al. (2013) · Hepatology · doi:10.1002/hep.26565 · Cited by 725
Self-citationHigh-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720
Self-citationHepatic and extrahepatic malignancies in primary sclerosing cholangitis
Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Lööf, L., Danielsson, Å., Hultcrantz, R., Lindgren, S., Prytz, H., Sandberg-Gertzén, H., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00288-4 · Cited by 717
Self-citationThirty-Year Analysis of a Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis
Rutter, M. D., Saunders, B. P., Wilkinson, K. H., Rumbles, S., Schofield, G., Kamm, M. A., Williams, C. B., Price, A. B., Talbot, I. C., & Forbes, A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.035 · Cited by 645
Research works printed but not linked: 6
- Boberg, 2002, Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation, Scand J Gastroenterol, 37, 1205, 10.1080/003655202760373434 · DOI
- Fevery, 2016, Patients with large-duct primary sclerosing cholangitis and Crohn’s disease have a better outcome than those with ulcerative colitis, or without IBD, Aliment Pharmacol Ther, 43, 612, 10.1111/apt.13516 · DOI · Paper page
- Rudolph, 2010, In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival, J Hepatol, 53, 313, 10.1016/j.jhep.2010.02.030 · DOI
- Boonstra, 2013, Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis, Hepatology, 58, 2045, 10.1002/hep.26565 · DOI · Paper page
- Bergquist, 2002, Hepatic and extrahepatic malignancies in primary sclerosing cholangitis, J Hepatol, 36, 321, 10.1016/S0168-8278(01)00288-4 · DOI · Paper page
- Lindor, 2009, High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis, Hepatology, 50, 808, 10.1002/hep.23082 · DOI · Paper page
Cited by
Sorted by citations
Items 201–300 of 534
Amelioration of Large Bile Duct Damage by Histamine-2 Receptor Vivo-Morpholino Treatment
Kennedy, L. L., Meadows, V., Kyritsi, K., Pham, L., Kundu, D., Kulkarni, R., Cerritos, K., Demieville, J., Hargrove, L. A., Glaser, S. S., et al. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.01.013 · Cited by 16
Emerging drugs for the treatment of primary sclerosing cholangitis
Abbas, N., Quraishi, M. N., & Trivedi, P. J. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.11.003 · Cited by 16
Self-citationLampinen, M., Vessby, J., Fredricsson, A., Wanders, A., Rorsman, F., & Carlson, M. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy170 · Cited by 16
Mutational Analysis of Bile Cell‐Free DNA in Primary Sclerosing Cholangitis: A Pilot Study
Arechederra, M., Bik, E., Rojo, C., Elurbide, J., Elizalde, M., Kruk, B., Krasnodębski, M., Pertkiewicz, J., Kozieł, S., Grąt, M., et al. (2025) · Liver International · doi:10.1111/liv.70049 · Cited by 15
Self-citationPrimary sclerosing cholangitis
von Seth, E., Karlsen, T. H., Tanaka, A., Ponsioen, C. Y., & Bergquist, A. M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02582-6 · Cited by 17
Self-citationMedication‐related osteonecrosis of the jaw: A disease of significant importance for older patients
Boston, B., Ipe, D. S., Căpitănescu, B., Greșiță, A., Hamlet, S. M., Love, R. M., Hadjiargyrou, M., Huang, C., Nusem, I., Miroiu, R. I., et al. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18414 · Cited by 15
Braadland, P. R., Bergquist, A. M., Kummen, M., Bossen, L., Engesæter, L. K., Reims, H. M., Björk, I., Grzyb, K., Abildgaard, A., Småstuen, M. C., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.038 · Cited by 16
Self-citationAutoimmune diseases in primary sclerosing cholangitis and their first-degree relatives
Båve, A. L., von Seth, E., Ingre, M., Nordenvall, C. A. M., & Bergquist, A. M. (2024) · Hepatology · doi:10.1097/hep.0000000000000823 · Cited by 15
Self-citationvan Rheenen, P. F., Kolho, K., Russell, R. K., Aloi, M., Deganello, A., Hussey, S., Junge, N., de Laffolie, J., Deneau, M. R., Fitzpatrick, E., et al. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12378 · Cited by 14
Novel histological scoring for predicting disease outcome in primary sclerosing cholangitis
Sjöblom, N., Boyd, S., Kautiainen, H., Arola, J., & Färkkilä, M. A. (2022) · Histopathology · doi:10.1111/his.14677 · Cited by 15
Self-citationBiron, A., Beaugerie, L., Chazouillères, O., & Kirchgesner, J. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17123 · Cited by 15
Self-citationZhang, L., Hu, Y., Qi, S., Zhang, C., Zhou, Q. Y., Zhang, D., Mu, Y., Zhang, H., Chen, G., Liu, P., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.965914 · Cited by 15
Pörner, D., Kaczmarek, D. J., Heling, D., Hausen, A., Mohr, R. U., Hüneburg, R., Matthaei, H., Glowka, T. R., Manekeller, S., Fischer, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74451-9 · Cited by 15
Self-citationRecent advances in the treatment of primary sclerosing cholangitis
Bjornsson, E. S., & Kalaitzakis, E. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1860751 · Cited by 18
Protective potential of the gallbladder in primary sclerosing cholangitis
Cazzagon, N., Gonzalez‐Sanchez, E., Mourabit, H. E., Wendum, D., Rainteau, D. P., Humbert, L., Corpechot, C., Chazouillères, O., Arrivé, L., Housset, C., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100649 · Cited by 14
Self-citationBloemen, H., Livanos, A. E., Martins, A., Dean, R., Bravo, A. C., Bourgonje, A. R., Tankelevich, M., Herb, J. T., Cho, J. H., Santos, A. A., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.10.005 · Cited by 14
Self-citationMedical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
Karlsen, T. H., Jørgensen, K. K., & Bergquist, A. M. (2024) · Hepatology · doi:10.1097/hep.0000000000001172 · Cited by 15
Self-citationPrimary sclerosing cholangitis and the management of uncertainty and complexity
Arndtz, K., & Hirschfield, G. M. (2017) · Frontline Gastroenterology · doi:10.1136/flgastro-2017-100815 · Cited by 14
Self-citationJoosse, M. E., Haisma, S. M., Sterk, M. F. M., van Munster, K. N., Ponsioen, C. Y., Houwen, R. H. J., Koot, B. G. P., de Meij, T. G. J., van Rheenen, P. F., & de Koning, B. A. E. (2019) · Liver International · doi:10.1111/liv.14159 · Cited by 14
Self-citationLampinen, M., Fredricsson, A., Vessby, J., Martinez, J. F., Wanders, A., Rorsman, F., & Carlson, M. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ma0517-175r · Cited by 14
Biliary atresia and liver transplantation in the United States: A contemporary analysis
Anouti, A., Patel, M. S., VanWagner, L. B., Lee, W. M., Fung, J. J., Cholankeril, G. T., Hwang, C. S., Mufti, A., Tujios, S. R., Kerr, T. A., et al. (2023) · Liver International · doi:10.1111/liv.15689 · Cited by 13
Primary sclerosing cholangitis is associated with abnormalities in CFTR
Werlin, S. L., Scotet, V., Uguen, K., Audrézet, M., Cohen, M., Yaakov, Y., Safadi, R., Ilan, Y., Konikoff, F. M., Galun, E., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.04.005 · Cited by 13
Aging‐Related Expression of Twinfilin‐1 Regulates Cholangiocyte Biological Response to Injury
Maroni, L., Pinto, C., Giordano, D. M., Saccomanno, S., Bañales, J. M., Spallacci, D., Albertini, M. C., Orlando, F., Provinciali, M., Milkiewicz, M., et al. (2018) · Hepatology · doi:10.1002/hep.30466 · Cited by 13
Self-citationNguyen, C., Kline, K. T., Stevenson, H. L., Khan, K. A., & Parupudi, S. V. J. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i3.495 · Cited by 13
Båve, A. L., Olén, O., Söderling, J. K., SWIBREG study Group, Ludvigsson, J. F., Bergquist, A. M., & Nordenvall, C. A. M. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12388 · Cited by 13
Self-citationRole of miR-506 in ulcerative colitis associated with primary sclerosing cholangitis
Kempińska‐Podhorodecka, A., Adamowicz, M., Ostrycharz, E., Chmielarz, M., Wójcicki, M., Milkiewicz, P., & Milkiewicz, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-89631-4 · Cited by 13
Self-citationCholangiocarcinoma: The era of liquid biopsy
Kotsifa, E., Saffioti, F., & Mavroeidis, V. K. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i11.104170 · Cited by 12
Self-citationNardelli, M. J., Bittencourt, P. L., Cançado, G. G. L., Faria, L. C., Villela‐Nogueira, C. A., Rotman, V., de Abreu, E. S., Osório, F. M. F., Evangelista, A. S., Mendes, L. S. C., et al. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/7746401 · Cited by 12
Liver transplant in primary sclerosing cholangitis: Current trends and future directions
Shah, Y. R., Nombera-Aznaran, N., Guevara-Lazo, D., Martinez, E. C., Tiwari, A., Kanumilli, S., Shah, P. C., Pinnam, B. S. M., Ali, H., & Dahiya, D. S. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i8.939 · Cited by 15
The Swedish initiative for the study of Primary sclerosing cholangitis (SUPRIM)
Cornillet, M., Villard, C., Rorsman, F., Molinaro, A., Nilsson, E., Kechagias, S., von Seth, E., & Bergquist, A. M. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102526 · Cited by 12
Self-citationAre Gender Differences Important for Autoimmune Liver Diseases?
Floreani, A., Gabbia, D., & Martin, S. D. (2024) · Life · doi:10.3390/life14040500 · Cited by 14
Self-citationNon-invasive diagnosis and follow-up of primary sclerosing cholangitis
Chazouillères, O., Potier, P., Bouzbib, C., Hanslik, B., Heurgué, A., Nguyen-Khac, É., Gournay, J., Tanné, F., Bureau, C., Bourlière, M., et al. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101775 · Cited by 12
Self-citationThe Inconvenient Truth of Primary Biliary Cholangitis/Autoimmune Hepatitis Overlap Syndrome
Hussain, N., & Trivedi, P. J. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.007 · Cited by 16
Self-citationCatassi, G. N., D’Arcangelo, G., Norsa, L., Bramuzzo, M., Hojsak, I., Kolho, K., Romano, C., Gasparetto, M., Giorgio, A. D., Hussey, S., et al. (2023) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izad218 · Cited by 12
Involvement of Autophagy in Ageing and Chronic Cholestatic Diseases
Pinto, C., Ninfole, E., Benedetti, A., Marzioni, M., & Maroni, L. (2021) · Cells · doi:10.3390/cells10102772 · Cited by 12
Self-citationLoesken, C., Maehder, K., Buck, L., Hartl, J., Löwe, B., Schramm, C., & Toussaint, A. C. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02645-2 · Cited by 11
Self-citationRennebaum, F., Demmig, C., Schmidt, H., Vollenberg, R., Tepasse, P., Trebicka, J., Gu, W., Ullerich, H., Kabar, I., & Cordes, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015431 · Cited by 11
Management of primary sclerosing cholangitis: Current state-of-the-art
Cançado, G. G. L., & Hirschfield, G. M. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000590 · Cited by 12
Self-citationJansson, H., Olthof, P. B., Bergquist, A. M., Ligthart, M. A. P., Nadalin, S., TROISI, R. I., Koerkamp, B. G., Alikhanov, R., Lang, H., Guglielmi, A., et al. (2021) · HPB · doi:10.1016/j.hpb.2021.04.011 · Cited by 11
Self-citationWeng, M., Shih, I., Tung, C., Leong, Y., Shieh, M., Wang, C.-Y., Wong, J., Ni, Y., & Wei, S. (2022) · Intestinal Research · doi:10.5217/ir.2021.00042 · Cited by 11
Marcus, E., Stone, P. C., Thorburn, D., Walmsley, M., & Vivat, B. (2022) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-022-00484-5 · Cited by 11
Self-citationNOTCH signalling – a core regulator of bile duct disease?
Lyons, A. M., & Boulter, L. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.050231 · Cited by 12
Evolving Practice and Changing Phenotype in Pediatric Autoimmune Liver Disease
Singh, H., Balouch, F., Noble, C., & Lewindon, P. J. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001927 · Cited by 11
Lee, W. S., Karthik, S. V., Ng, R. T., Ong, S. Y., Ong, C., Chiou, F. K., Wong, S. Y., Quak, S. H., & Aw, M. (2018) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2018.09.007 · Cited by 11
Recurrent Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Directions
Leung, K. K., Deeb, M., Fischer, S. E., & Gulamhusein, A. F. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730950 · Cited by 12
Are, V. S., Gómez, E. V., Gromski, M. A., Akisik, F. M., Lammert, C. S., Ghabril, M., Chalasani, N., Vuppalanchi, R., & Nephew, L. D. (2021) · Liver International · doi:10.1111/liv.15008 · Cited by 11
Choi, Y., & Kim, N. (2022) · Springer eBooks · doi:10.1007/978-981-19-0120-1_19 · Cited by 11
Primary Sclerosing Cholangitis Limited to Intrahepatic Bile Ducts Has Distinctly Better Prognosis
Are, V. S., Gromski, M. A., Akisik, F. M., Vilar‐Gómez, E., Lammert, C. S., Ghabril, M., Vuppalanchi, R., & Chalasani, N. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-08260-1 · Cited by 10
PSC and colitis: A complex relationship
Horst, L. J., Kempski, J., Walmsley, M., Huber, S., & Schramm, C. (2025) · Hepatology · doi:10.1097/hep.0000000000001236 · Cited by 11
Self-citationCholangiocarcinoma and liver transplantation: What we know so far?
Safarpour, A. R., Askari, H., Ejtehadi, F., Azarnezhad, A., Raeis-Abdollahi, E., Tajbakhsh, A., Abazari, M. F., Tarkesh, F., Shamsaeefar, A., Niknam, R., et al. (2021) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v12.i5.84 · Cited by 10
Holm, M., Joenväärä, S., Saraswat, M., Tohmola, T., Saarela, T., Tenca, A., Arola, J., Renkonen, R., & Färkkilä, M. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272810 · Cited by 10
Self-citationJadaun, S. S., Mehtani, R., Hasnain, A., Bhatia, S., Moond, V., Kumar, M., Kuhad, V., Singh, S. A., Agarwal, S. K., Gupta, S. C., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10442-4 · Cited by 11
Primary sclerosing cholangitis—A long night's journey into day
Chapman, R. W. (2022) · Clinical Liver Disease · doi:10.1002/cld.1264 · Cited by 9
Self-citationPrecision medicine in primary sclerosing cholangitis
Maurice, J. B., & Thorburn, D. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12788 · Cited by 10
Self-citationUmetsu, S., Notohara, K., Nakazawa, T., Tsunoda, T., Sogo, T., Komatsu, H., Tanaka, A., Tazuma, S., Takikawa, H., Inui, A., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13421 · Cited by 10
Lopens, S., Krawczyk, M. J., Papp, M., Milkiewicz, P., Schierack, P., Liu, Y., Wunsch, E., Conrad, K., & Roggenbuck, D. (2020) · Autoimmunity Highlights · doi:10.1186/s13317-020-00129-x · Cited by 10
Self-citationCatanzaro, E., Gringeri, E., Cazzagon, N., Floreani, A., Cillo, U., Burra, P., & Gambato, M. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14030222 · Cited by 10
Self-citationSTAT activation in regulatory CD4+ T cells of patients with primary sclerosing cholangitis
Dold, L., Kalthoff, S., Frank, L., Zhou, T., Esser, P. L., Lutz, P. L., Strassburg, C. P., Spengler, U., & Langhans, B. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1248 · Cited by 9
Self-citationHolmer, M., Ingre, M., Färkkilä, M. A., Ponsioen, C. Y., Mol, B., Schramm, C., Folseraas, T., Wiencke, K., Cazzagon, N., Catanzaro, E., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001351 · Cited by 9
Self-citationAttauabi, M., Wewer, M. D., Bendtsen, F., Seidelin, J. B., & Burisch, J. M. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac003 · Cited by 9
Cholangiocarcinoma Surveillance Recommendations in Patients with Primary Sclerosing Cholangitis
Saca, D., & Flamm, S. L. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.07.010 · Cited by 9
Prognostic models and autoimmune liver diseases
D’Amato, D., & Carbone, M. (2023) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2023.101878 · Cited by 10
Petersen, D. R., Orlicky, D. J., Roede, J. R., & Shearn, C. T. (2018) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2018.05.012 · Cited by 9
Baghaei, A., Emami, M. H., Adibi, P., Tavakkoli, H., Daghaghzadeh, H., Tamizifar, B., Akbarpour, M., & Hojjatpour, B. (2019) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_316_17 · Cited by 9
Management of Autoimmune Liver Diseases after Liver Transplantation
Barba, R., Medina‐Morales, E., Goyes, D., Patwardhan, V. R., & Bonder, A. (2021) · Transplantology · doi:10.3390/transplantology2020016 · Cited by 9
Implications of gut microbiota in autoimmune liver diseases
Qian, Q., He, W., Tang, R., & Ma, X. (2021) · Minerva Gastroenterology · doi:10.23736/s2724-5985.21.02860-9 · Cited by 9
Ringe, K. I., Grigoriadis, A., Halibasic, E., Wacker, F. K., Manns, M. P., Schramm, C., Lenzen, H., & on behalf of the MRI working group of the IPSCSG (2018) · Hepatology · doi:10.1002/hep.30276 · Cited by 9
Self-citationBranchi, V., Hosni, R., Kiwitz, L., Ng, S. S., van der Voort, G., Bambi, N., Kleinfelder, E., Esser, L. K., Dold, L., Langhans, B., et al. (2024) · Human Pathology · doi:10.1016/j.humpath.2024.105670 · Cited by 8
Viganò, C., Laffusa, A., Pirola, L., Cristoferi, L., Zuin, G., Sansotta, N., Daphne, D., Stefania, O., Medici, F., Carlo, A. S., et al. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2550518 · Cited by 9
Self-citationFischer, H., & Goltz, D. (2020) · Der Pathologe · doi:10.1007/s00292-020-00807-7 · Cited by 8
Ali, A. H., Juran, B. D., Schlicht, E. M., Bianchi, J. K., McCauley, B. M., Atkinson, E. J., & Lazaridis, K. N. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01930-2 · Cited by 8
Self-citationVessby, J., Wiśniewski, J. R., Lindskog, C., Eriksson, N., Gabrysch, K., Zettl, K., Wanders, A., Carlson, M., Rorsman, F., & Åberg, M. (2022) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000486 · Cited by 8
Yazdanfar, M., Zepeda, J., Dean, R. D., Wu, J., Levy, C., Goldberg, D. S., Lammert, C. S., Prenner, S. B., Reddy, K. R., Pratt, D. S., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000366 · Cited by 8
Self-citationPharmacologic management of primary sclerosing cholangitis: what’s in the pipeline?
Suri, J. S., Patwardhan, V. R., & Bonder, A. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1636647 · Cited by 8
Weismüller, T. J., Zhou, T., Kalthoff, S., Lenzen, H., Manns, M. P., & Strassburg, C. P. (2020) · Liver International · doi:10.1111/liv.14487 · Cited by 8
Self-citationSclerosing cholangitis in a patient treated with nivolumab
Talbot, S., MacLaren, V., & Lafferty, H. D. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-241700 · Cited by 8
Cholangiocarcinoma: early detection and screening in high-risk population
Muñoz, S., Rimola, J., Londoño, M., Cárdenas, A., & Forner, A. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2022.22 · Cited by 8
Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis
Dhillon, A. K., Kremer, A. E., Kummen, M., Boberg, K. M., Elferink, R. P. J. O., Karlsen, T. H., Beuers, U. H., Vesterhus, M. N., & Hov, J. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-44762-7 · Cited by 8
Self-citationClinical Characterization of Ulcerative Colitis in Patients with Primary Sclerosing Cholangitis
Murasugi, S., Ito, A., Omori, T., Nakamura, S., & Tokushige, K. (2020) · Gastroenterology Research and Practice · doi:10.1155/2020/7969628 · Cited by 8
Özdirik, B., Veltzke-Schlieker, W., Nicklaus, J. M., Berger, H., Schmidt, D. N., Leonhardt, S., Penndorf, V., Adler, A., Müller, T., Wree, A., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000494 · Cited by 7
Zhou, T., Lenzen, H., Dold, L., Bündgens, B., Wedemeyer, H. H., Manns, M. P., Gonzalez-Carmona, M. A., Strassburg, C. P., & Weismüller, T. J. (2021) · Liver International · doi:10.1111/liv.15028 · Cited by 7
Self-citationSayed, A., Assis, D. N., Silveira, M. G., Deng, Y., Ciarleglio, M. M., Gaidos, J. K. J., Proctor, D. D., & Al‐Bawardy, B. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002510 · Cited by 7
Dong, X., Gong, L.-L., Hong, M., & Pan, J. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03162-6 · Cited by 7
Fung, B. M., & Tabibian, J. H. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1900732 · Cited by 7
Maternal obesogenic diet enhances cholestatic liver disease in offspring
Thompson, M. D., Hinrichs, H., Faerber, A., Tarr, P. I., & Davidson, N. O. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100205 · Cited by 7
de Krijger, M., Hageman, I., Yim, A. Y. F. L., Verhoeff, J., García-Vallejo, J. J., van Hamersveld, P. H. P., Levin, E., Hakvoort, T. B. M., Wildenberg, M. E., Henneman, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840935 · Cited by 7
Self-citationManaging abnormal liver tests in children with inflammatory bowel disease
van Rheenen, P. F. (2021) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001045 · Cited by 8
Slooter, C. D., van den Brand, F. F., Lleò, A., Liberal, R., & de Boer, Y. S. (2023) · Hepatology · doi:10.1097/hep.0000000000000689 · Cited by 7
Grant, C. W., Juran, B. D., Ali, A. H., Schlicht, E. M., Bianchi, J. K., Hu, X. Y., Liang, Y., Jarrell, Z. R., Liu, K., Go, Y., et al. (2023) · Exposome · doi:10.1093/exposome/osac011 · Cited by 6
Self-citationKahan, T. F., Marenco‐Flores, A., Rojas-Amaris, N., Barba, R., Goyes, D., Medina‐Morales, E., Sierra, L., Patwardhan, V. R., & Bonder, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14062098 · Cited by 6
Autorinnen/Autoren, & Collaborators (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2558-5204 · Cited by 6
Shi, H., Dou, D., Zhang, F., Du, Y., Zhao, L., Zhi, J., & Zhao, L. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70018 · Cited by 6
Wu, G., Xu, X., Zhang, H., Li, P., & Liu, C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1705162 · Cited by 8
Hepatobiliary Impairments in Patients with Inflammatory Bowel Diseases: The Current Approach
Ionescu, V. A., Gheorghe, G., Varlas, V. N., Stănescu, A. M. A., & Diaconu, C. C. (2022) · Gastroenterology Insights · doi:10.3390/gastroent14010002 · Cited by 6
An overview of recent treatment options for primary sclerosing cholangitis
Mousavere, I. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0834 · Cited by 8
Influence of Sex in the Development of Liver Diseases
Zhang, J., Zhang, N., Lyu, Y., & Zhang, X. (2025) · Seminars in Liver Disease · doi:10.1055/a-2516-0261 · Cited by 7
CTLA-4 Expression Plays a Role in PSC and PBC Progression
Meister, P., Steinke-Ramming, C., Beste, M., Lenzen, H., Gerken, G., Canbay, A. E., & Jochum, C. (2020) · Diseases · doi:10.3390/diseases8020021 · Cited by 6
Self-citationHuang, Y. G., Zhang, S., Weng, J., Huang, D., & Gu, W. (2022) · Open Medicine · doi:10.1515/med-2022-0481 · Cited by 6
Lopens, S., Wunsch, E., Milkiewicz, M., Röber, N., Zarske, G., Nasser, A., Conrad, K., Laass, M. W., Rödiger, S., Krawczyk, M. J., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12112682 · Cited by 6
Self-citationNguyen, A., Sagvand, B. T., Alizadeh, M. A., Nguyen, C., Scott, W. A., & von Rosenvinge, E. C. (2023) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2022.1076788 · Cited by 6
Metadata
- Authors
- Weismüller, T. J., Trivedi, P. J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C. Y., Holm, K., Gotthardt, D., Färkkilä, M. A., Marschall, H.-U., Thorburn, D., Weersma, R. K., Fevery, J., Mueller, T., Chazouillères, O., Schulze, K., Lazaridis, K. N., Almer, S., Pereira, S. P., Levy, C., Mason, A., Naess, S., Bowlus, C. L., Floreani, A., Halilbasic, E., Yimam, K. K., Milkiewicz, P., Beuers, U., Huynh, D. K., Pares, A., Manser, C. N., Dalekos, G. N., Eksteen, B., Invernizzi, P., Berg, C. P., Kirchner, G. I., Sarrazin, C., Zimmer, V., Fabris, L., Braun, F., Marzioni, M., Juran, B. D., Said, K., Rupp, C., Jokelainen, K., Benito de Valle, M., Saffioti, F., Cheung, A., Trauner, M., Schramm, C., Chapman, R. W., Karlsen, T. H., Schrumpf, E., Strassburg, C. P., Manns, M. P., Lindor, K. D., Hirschfield, G. M., Hansen, B. E., & Boberg, K. M.
- Affiliations
- University of Bonn (DE)
- Queen Elizabeth Hospital Birmingham (GB)
- Karolinska University Hospital (SE)
- Mayo Clinic (US)
- Medizinische Hochschule Hannover (DE)
- Amsterdam UMC Location University of Amsterdam (NL)
- Oslo University Hospital (NO)
- University Hospital Heidelberg (DE)
- University of Helsinki (FI)
- University of Gothenburg (SE)
- The Royal Free Hospital (GB)
- University Medical Center Groningen (NL)
- Universitair Ziekenhuis Leuven (BE)
- Charité – Universitätsmedizin Berlin (DE)
- Assistance Publique – Hôpitaux de Paris (FR)
- University Medical Center Hamburg-Eppendorf (DE)
- Linköping University (SE)
- University College London (GB)
- University of Miami (US)
- University of Alberta (CA)
- University of California, Davis (US)
- University of Padua (IT)
- Medical University of Vienna (AT)
- California Pacific Medical Center (US)
- Medical University of Warsaw (PL)
- Royal Adelaide Hospital (AU)
- University Hospital Zurich (CH)
- University of Calgary (CA)
- University of Milan (IT)
- University of Tübingen (DE)
- University Hospital Regensburg (DE)
- Goethe University Frankfurt (DE)
- Universitätsklinikum des Saarlandes (DE)
- University Hospital Schleswig-Holstein (DE)
- Marche Polytechnic University (IT)
- John Radcliffe Hospital (GB)
- National Institute for Health and Care Research (GB)
- University of Toronto (CA)
- Corresponding author
- Weismüller, Tobias J.
- Boberg, Kirsten M.
- ORCID
- Weismüller, Tobias J.
- Trivedi, Palak J.
- Bergquist, Annika
- Imam, Mohamad
- Lenzen, Henrike
- Ponsioen, Cyriel Y.
- Holm, Kristian
- Gotthardt, Daniel
- Färkkilä, Martti A.
- Marschall, Hanns-Ulrich
- Thorburn, Douglas
- Weersma, Rinse K.
- Fevery, Johan
- Mueller, Tobias
- Chazouillères, Olivier
- Schulze, Kornelius
- Lazaridis, Konstantinos N.
- Almer, Sven
- Pereira, Stephen P.
- Levy, Cynthia
- Mason, Andrew
- Bowlus, Christopher L.
- Floreani, Annarosa
- Halilbasic, Emina
- Milkiewicz, Piotr
- Beuers, Ulrich
- Eksteen, Bertus
- Invernizzi, Pietro
- Berg, Christoph P.
- Zimmer, Vincent
- Fabris, Luca
- Braun, Felix
- Marzioni, Marco
- Said, Karouk
- Rupp, Christian
- Saffioti, Francesca
- Cheung, Angela
- Trauner, Michael
- Schramm, Christoph
- Chapman, Roger W.
- Karlsen, Tom H.
- Strassburg, Christian P.
- Manns, Michael P.
- Lindor, Keith D.
- Hirschfield, Gideon M.
- Hansen, Bettina E.
- Boberg, Kirsten M.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 152
- Issue
- 8
- Pages
- 1975-1984.e8
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC5546611
- OpenAlex
- W2594589478
- Cited by
- 533
- References
- 74
- Citations by year
- 2026: 49 · 2025: 58 · 2024: 60 · 2023: 65 · 2022: 59 · 2021: 68 · 2020: 55 · 2019: 43 · 2018: 49 · 2017: 24
- FWCI
- 28.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by-nc-nd)
- UCL Discovery (University College London) (submittedVersion)
- University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Työväentutkimus Vuosikirja (submittedVersion, other-oa)
- University of Thessaly Institutional Repository (University of Thessaly) (submittedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by-nc-nd)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Wellcome Trust
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK084960)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- primary sclerosing cholangitis, inflammatory bowel disease, cholangiocarcinoma, liver transplantation, disease progression, age at diagnosis, sex differences, Crohn's disease, ulcerative colitis, IBD surgery, mortality
- MeSH terms
- Adult, Australia, Colitis, Ulcerative, Crohn Disease, Europe, Female, Humans, Male, Middle Aged, North America, Phenotype, Prognosis, Retrospective Studies, Risk Factors, Time Factors, Cholangitis, Sclerosing, Incidence, Multivariate Analysis, Chi-Square Distribution, Proportional Hazards Models, Liver Transplantation, Age Distribution, Sex Distribution, Disease Progression, Risk Assessment, Kaplan-Meier Estimate, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
